When was Revance Therapeutics founded?

Revance Therapeutics was founded in 2002 and raised its 1st funding round 5 years after it was founded.

Where is Revance Therapeutics located?

Revance Therapeutics is headquartered in Newark, United States. It is registered at Newark (United States).

Who is the current CEO of Revance Therapeutics?

Dan Browne of Revance Therapeutics.

How many employees does Revance Therapeutics have?

As of Dec 31, 2023, Revance Therapeutics has 597 employees, reflecting a 12% year-over-year growth in headcount.

Is Revance Therapeutics a funded company?

Revance Therapeutics is a funded company, having raised a total of $155M across 5 funding rounds to date. The company's 1st funding round was a $***** Series C round, raised on Dec 12, 2007.

When was the latest funding round of Revance Therapeutics?

Revance Therapeutics' latest funding was a $***** Series E round on Oct 22, 2013, with participation from 0 investor. Its primary sector is Dermatology. In United States, the Dermatology sector has seen $165M in funding in 2026 to date.

What is the annual revenue of Revance Therapeutics?

Annual revenue of Revance Therapeutics is $234M as on Dec 31, 2023.

Where does Revance Therapeutics rank among its competitors?

Revance Therapeutics ranks 1st amongst 168 active competitors, of which 41 are funded. It stands 2nd in terms of total funding among its competitors. The most recent competitor to raise funding was Collplant, which secured $4M in Feb, 2026.

Who are the top competitors of Revance Therapeutics?

Revance Therapeutics' top competitors include Evolus, Dermavant and Clinuvel. Among them, Collplant secured the most recent funding round in February, 2026.

Revance Therapeutics - 2026 Company Profile, Team, Funding, Competitors & Financials

Revance Therapeutics is an acquired company based in Newark (United States), founded in 2002 by Dan Browne. It operates as a Developer of neurotoxin aesthetic and therapeutic products for skin treatments. Revance Therapeutics has raised $155M in funding from investors like EW Healthcare Partners, Delphi Ventures and Medicis Pharmaceutical. The company has 168 active competitors, including 41 funded and 60 that have exited. Its top competitors include companies like Evolus, Dermavant and Clinuvel.

Company Details

Developer of neurotoxin aesthetic and therapeutic products for skin treatments. It focused on developing innovative products in the aesthetic medicine and personal wellness categories. It has developed a platform technology that enables the delivery of large macromolecules and other potent molecules across the skin. Its aesthetics pipeline includes RT001 for lateral canthal lines and RT002 for glabellar lines. It has the same products as therapies for Hyperhidrosis and Cervical Dystonia.

Website: revance.com
Social
Phone Number: +1 **********
Registered Address: Newark (United States)

Key Metrics

Founded Year

2002

Location

Newark, United States

Stage

Acquired

Total Funding

$155M in 5 rounds

Latest Funding Round

Series E, Oct 22, 2013, $*****

Investors

EW Healthcare Partners & 17 more

Ranked

1^st among 168 active competitors

Annual Revenue

$234M as on Dec 31, 2023

Employee Count

597 as on Dec 31, 2023

Investment & Acquisitions

HintMD

Similar Companies

Evolus & 224 more

Exit Details

Acquired by Crown Laboratories (Feb 08, 2025)

View Revance Therapeutics' full profile

Revance Therapeutics is associated with 3 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Revance Therapeutics, Inc., CIN: 77-0551645 , United States, Active	Dec 31, 2001	-	495 (As on Dec 31, 2021)	-
Revance Therapeutics, Inc. CIN: 1479290 , United States, Active	Dec 22, 2009	$234M (As on Dec 31, 2023)	597 (As on Dec 31, 2023)	-
Revance Therapeutics, Inc. CIN: 001t000000scXuxAAE , United States, Active	Apr 25, 2022	-	-	-

Revance Therapeutics got acquired by Crown Laboratories on Feb 08, 2025.

Click here to take a look at Revance Therapeutics's acquisition in detail

Revance Therapeutics has raised a total funding of $155M over 5 rounds. Its first funding round was on Dec 12, 2007. Revance Therapeutics has 18 institutional investors.

Here is the list of recent funding rounds of Revance Therapeutics:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Oct 22, 2013	8780913	Series E	6002647	2762912	8661796	9247780
Feb 22, 2013	5288871	Series E	7525170	8942324	5210794	6716578
Jan 08, 2013	8262502	Series D	6485086	1339424	EW Healthcare Partners & 1 more	Quintiles & 6 more

Access funding benchmarks and valuations. Sign up today!

View details of Revance Therapeutics's funding rounds and investors

The founders of Revance Therapeutics is Dan Browne.

Here are the details of Revance Therapeutics' key team members:

Dan Browne: Co-Founder & President & CEO of Revance Therapeutics. They serve on the board of 1 company.

View details of Revance Therapeutics's Founder profiles and Board Members

Revance Therapeutics' employee count trend

Revance Therapeutics has 597 employees as of Dec 23. The total employee count is 12.0% more than what it was in Dec 22. Here is Revance Therapeutics's employee count trend over the years:

Employee count trend for Revance Therapeutics

Uncover Revance Therapeutics' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Revance Therapeutics include Evolus, Dermavant and Clinuvel. Here is the list of Top 10 competitors of Revance Therapeutics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Revance Therapeutics 2002, Newark (United States), Acquired	Developer of neurotoxin aesthetic and therapeutic products for skin treatments	$155M	Vivo Capital, Athyrium Capital Management ... & 16 others	72/100
2nd	Evolus 2012, Irvine (United States), Public	Developer of aesthetic treatments and procedures	$500K	Daewoong Pharmaceutical, De novo ventures	67/100
3rd	Dermavant 2016, Phoenix (United States), Acquired	Developer of small molecule based therapeutics for the treatment of inflammatory skin diseases	$160M	Marathon Asset Management, NovaQuest Capital Management ... Read more	61/100
4th	Clinuvel 2001, Melbourne (Australia), Public	Biopharma company focused on developing drugs for skin disorders	$51M	-	61/100
5th	Sol-Gel Technologies 1998, United States, Public	Developing topical drug products for the treatment of rosacea, acne and interdigital tinea pedis.	$26M	Westwicke, Arkin Holdings & 6 others	59/100
6th	Collplant 2004, Ness Ziona (Israel), Public	Developer of recombinant human collagen for regenerative medicine and aesthetics	$16.3M	Invesco, Pontifax & 4 others	59/100
7th	Lineage Cell Therapeutics 1990, Carlsbad (United States), Public	Developer of cell based therapies for the treatment of cancer, eye disease and spinal disorders	$45.8M	Juvenescence, NIH & 4 others	59/100
8th	Biofrontera 1997, Leverkusen (Germany), Public	Developer of therapies for actinic keratosis using photodynamic therapy	-	Rosalind Advisors, Deutsche Balaton & 1 others	56/100
9th	Medytox 2000, Seoul (South Korea), Public	Developing botulinum toxins, synthetic drugs, supplements & medical devices	-	Atinum Investment, STIC Investments & 8 others	55/100
10th	Clock.bio 2020, Cambridge (United Kingdom), Seed	Developer of treatments for age-related diseases using human pluripotent stem cells	$9.93M	LocalGlobe, Skyworthdigital & 6 others	55/100

Get insights and benchmarks for competitors of 2M+ companies! Sign up today!

Looking for more details on Revance Therapeutics's competitors? Click here to see the top ones

Revance Therapeutics has acquired HintMD. Revance Therapeutics has not made any investments as of now.

Here is the latest report on Revance Therapeutics's sector:

Free

Dermatology - Sector Report

Edition: November, 2025 (68 Pages)

View all reports related to Revance Therapeutics

Media has covered Revance Therapeutics for a total of 10 events in the last 1 year, 3 of them have been about company updates and 2 about people movement.